Skip to main content
. Author manuscript; available in PMC: 2022 Nov 16.
Published in final edited form as: Sci Transl Med. 2022 Nov 2;14(669):eabq4433. doi: 10.1126/scitranslmed.abq4433

Fig. 3. A quantitative score reflective of immune dysfunction severity.

Fig. 3

(A) Diffusion map estimated using the Extended gene signature. Colors indicate SRS group; shapes indicate profiling platforms. (B) Distribution of SRSq across cohorts. p = Kruskal-Wallis test p value. (C) Association between SRSq and mortality in GAinS, as determined using a sliding window approach. Shades represent 95% confidence intervals. (D) Estimated hazard ratios and 95% confidence intervals. (E) SRSq values stratified by ICU-acquired infection score (ICU-AI). β = regression coefficient; p = regression p value. (F) Kaplan-Meier curves of 28-day survival in patients sampled at multiple time points. Patients were stratified into quartiles based on their rate of SRSq reduction over time. Shades indicate 95% confidence intervals. p = log-rank test p value. (G) Association between rate of SRSq reduction and mortality, as determined using a sliding window. Shades represent 95% confidence intervals. (H) Causal model assumed for mediation analysis. Arrows represent causal directions. (I) Mediation effects. Lines indicate 95% confidence intervals, with solid and dotted lines corresponding to the treatment (high SRSq) and control (low SRSq) conditions. ACME = Average Causal Mediation Effect; ADE = Average Direct Effect; p = mediation p value.